Paroxysmal nocturnal hemoglobinuria in children

Pediatric Drugs

Volumn 9, Issue 1, 2007, Pages 11-16

  Van Den Heuvel Eibrink, Marry M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANDROGEN; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ECULIZUMAB; FOLIC ACID; GLYCAN DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; IRON; MELPHALAN; PHOSPHATIDYLINOSITOL; PREDNISOLONE; THYMOCYTE ANTIBODY;

ANEMIA; ANTICOAGULANT THERAPY; APLASTIC ANEMIA; BLOOD TRANSFUSION; BONE MARROW DEPRESSION; CLINICAL FEATURE; CONVALESCENCE; CORTICOSTEROID THERAPY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; HEMATOPOIETIC CELL; HEPARINIZATION; HORMONAL THERAPY; HUMAN; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTRAVASCULAR HEMOLYSIS; IRON THERAPY; MOLECULAR CLONING; MYELODYSPLASTIC SYNDROME; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RELIABILITY; REVIEW; SOMATIC MUTATION; SPLENECTOMY; STEM CELL TRANSPLANTATION; THROMBECTOMY; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION; WHOLE BODY RADIATION;

ANTIGENS, CD55; ANTIGENS, CD59; CHILD; GLYCOSYLPHOSPHATIDYLINOSITOLS; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; MUTATION;

EID: 33847051597     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200709010-00002     Document Type: Review

References (47)

1. Strübing P. Paroxysmale hämoglobinurie. Deutsche Medicinische Wochenschrift 1882; 8: 17-21
2. Parker CJ. Historical aspects of paroxysmal nocturnal haemoglobinuria: 'defining the disease'. Br J Haematol 2002; 117 (1): 3-22
3. Low MG, Finean JB. Release of alkaline phosphatase from membranes by a phosphatidylinositol-specific phospholipase C. Biochem J 1977; 167: 281-4
4. Miyata T, Takeda J, Iida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993; 259 (5099): 1318-20
5. Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993; 73 (4): 703-11
6. Nishimura J, Phillips KL, Ware RE, et al. Efficient retrovirus-mediated PIG-A gene transfer and stable restoration of GPI-anchored protein expression in cells with the PNH phenotype. Blood 2001; 97 (10): 3004-10
7. Karadimitris A, Luzzatto L. The cellular pathogenesis of paroxysmal nocturnal haemoglobinuria. Leukemia 2001; 15 (8): 1148-52
8. Risitano AM, Holada K, Chen G, et al. CD34+ cells from paroxysmal nocturnal hemoglobinuria (PNH) patients are deficient in surface expression of cellular prion proein (PrPc). Exp Hematol 2003; 31: 65-72
9. Rizk S, Ibrahim IY, Mansour IM, et al. Screening for paroxysmal nocturnal hemoglobinuria (PNH) clone in Egyptian children with aplastic anemia. J Trop Pediatr 2002; 48 (3): 132-7
10. Ware RE, Hall SE, Rosse WF. Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N Engl J Med 1991; 325 (14): 991-6
11. Meletis J, Terpos E. Recent insights into the pathophysiology of paroxysmal nocturnal hemoglobinuria. Med Sci Monit 2003; 9 (7): RA161-72
12. Flotho C, Strahm B, Kontny U, et al. Stem cell transplantation for paroxysmal nocturnal haemoglobinuria in childhood. Br J Haematol 2002; 118 (1): 124-7
13. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106 (12): 3699-709
14. Wainwright L, Brodsky RA, Erasmus LK, et al. Paroxysmal nocturnal hemoglobinuria arising from Fanconi anemia. J Pediatr Hematol Oncol 2003; 25 (2): 167-8
15. Nathan D, Oski F. Nathan and Oski's hematology of infancy and childhood. 6th ed. Philadelphia (PA): W.B. Saunders, 2003
16. Hillmen P, Richards SJ. Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2000; 108 (3): 470-9
17. Young NS, Maciejewski JP. Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes 'Why? Why? Why?' J Clin Invest 2000; 106 (5): 637-41
18. Karadimitris A, Manavalan JS, Thaler HT, et al. Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood 2000; 96 (7): 2613-20
19. Takahashi Y, McCoy Jr JP, Carvallo C, et al. In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation. Blood 2004; 103 (4): 1383-90
20. Hall C, Richards SJ, Hillmen P. The glycosylphosphatidylinositol anchor and paroxysmal nocturnal haemoglobinuria/aplasia model. Acta Haematol 2002; 108 (4): 219-30
21. Richards SJ, Rawstron AC, Hillmen P. Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry 2000; 42 (4): 223-33
22. Mortazavi Y, Merk B, McIntosh J, et al. The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot. Blood 2003; 101 (7): 2833-41
23. Nafa K, Bessler M, Castro-Malaspina H, et al. The spectrum of somatic mutations in the PIG-A gene in paroxysmal nocturnal hemoglobinuria includes large deletions and small duplications. Blood Cells Mol Dis 1998; 24 (3): 370-84
24. Wang H, Chuhjo T, Yasue S, et al. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 2002; 100 (12): 3897-902
25. Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999; 131 (6): 401-8
26. van den Heuvel-Eibrink MM, Bredius RG, te Winkel ML, et al. Childhood paroxysmal nocturnal haemoglobinuria (PNH), a report of 11 cases in the Netherlands. Br J Haematol 2005; 128 (4): 571-7
27. Miller DR, Baehner RL, Diamond LK. Paroxysmal nocturnal hemoglobinuria in childhood and adolescence: clinical and erythrocyte metabolic studies in two cases. Pediatrics 1967; 39 (5): 675-88
28. Kletzel M, Arnold WC, Berry DH. Paroxysmal nocturnal hemoglobinuria presenting as recurrent hemolytic uremic syndrome. Clin Pediatr (Phila) 1987; 26 (6): 319-20
29. Wyatt HA, Mowat AP, Layton M. Paroxysmal nocturnal haemoglobinuria and Budd-Chiari syndrome. Arch Dis Child 1995; 72 (3): 241-2
30. Graham ML, Rosse WF, Halperin EC, et al. Resolution of Budd-Chiari syndrome following bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1996; 92 (3): 707-10
31. Endo M, Beatty PG, Vreeke TM, et al. Syngeneic bone marrow transplantation without conditioning in a patient with paroxysmal nocturnal hemoglobinuria: in vivo evidence that the mutant stem cells have a survival advantage. Blood 1996; 88 (2): 742-50
32. Lin HC, Chen RL, Wang PJ. Paroxysmal nocturnal hemoglobinuria presenting as moyamoya syndrome. Brain Dev 1996; 18 (2): 157-9
33. Hill A, Ridley SH, Esser D, et al. Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. Blood 2006; 107 (5): 2131-7
34. Parker CJ. An overview of specific inhibitors of complement: opportunities for therapy of paroxysmal nocturnal hemoglobinuria and related disorders. In: Omine M, Kinoshita T, eds. Paroxysmal nocturnal hemoglobinuria and related disorders: molecular aspects of pathogenesis. Tokyo: Springer, 2003: 11-23
35. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350 (6): 552-9
36. Hill A, Rother RP, Hillmen P. Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria. E-case Haematologica 2005; 90: ECR40
37. Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005; 106 (7): 2559-65
38. Issaragrisil S, Piankijagum A, Tang-naitrisorana Y. Corticosteroids therapy in paroxysmal nocturnal hemoglobinuria. Am J Hematol 1987; 25 (1): 77-83
39. Rosse WF. Treatment of paroxysmal nocturnal hemoglobinuria. Blood 1982; 60 (1): 20-3
40. Hartmann RC, Jenkins Jr DE, McKee LC, et al. Paroxysmal nocturnal hemoglobinuria: clinical and laboratory studies relating to iron metabolism and therapy with androgen and iron. Medicine (Baltimore) 1966; 45 (5): 331-63
41. Monagle P, Chan A, Massicotte P, et al. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl.): 645S-87S
42. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 2003; 102 (10): 3587-91
43. Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 1996; 348 (9027): 573-7
44. Antin JH, Ginsburg D, Smith BR, et al. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. Blood 1985; 66 (6): 1247-50
45. Storb R, Evans RS, Thomas ED, et al. Paroxysmal nocturnal haemoglobinuria and refractory marrow failure treated by marrow transplantation. Br J Haematol 1973; 24 (6): 743-50
46. Epperson DE, Nakamura R, Saunthararajah Y, et al. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001; 25 (12): 1075-83
47. Inukai T, Sugita K, Goto M, et al. Spontaneous recovery from pancytopenia in a young female patient with paroxysmal nocturnal hemoglobinuria (PNH): changes in the GPI-anchor expression on peripheral blood cells. Rinsho Ketsueki 2004; 45 (3): 238-42